The effect of symptom duration in epithelial ovarian cancer on prognostic factors

  • Joseph Menczer
  • Angela Chetrit
  • Siegal Sadetzki
  • for the National Israel Ovarian Cancer Group
Original Article

Abstract

Purpose

To assess the association between duration of symptoms and main prognostic factors of invasive epithelial ovarian cancer (EOC).

Methods

The data of all histologically confirmed EOC patients diagnosed in Israel during the period 1994–1999 (n = 1,005) were retrieved from discharge summaries and admission records. Of the 371 (36.9%) patients with known presenting symptoms, the durations of 187 (50.4%) were recorded.

Results

The most common presenting symptoms were abdominal pain (65.2%). The percentage of patients with three or more symptoms increased significantly with stage (P = 0.001). No statistically significant association between duration of symptoms and prognostic factors was found.

Conclusion

Our findings did not show an association between duration of symptoms and prognostic factors in EOC patients and may indicate that prognosis is not a function of delay in diagnosis.

Keywords

Symptom duration Ovarian carcinoma Prognostic factors 

Notes

Conflict of interest statement

None.

References

  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15–36PubMedCrossRefGoogle Scholar
  2. 2.
    Berkenblit A, Cannistra SA (2005) Advances in the management of epithelial ovarian cancer. J Reprod Med 50:426–438PubMedGoogle Scholar
  3. 3.
    Eisenhauer EA, Gore M, Neijt JP (1999) Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 10:S9–S15. doi: 10.1023/A:1008343015697 CrossRefGoogle Scholar
  4. 4.
    Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA et al (1996) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335:1413–1416. doi: 10.1056/NEJM199611073351901 PubMedCrossRefGoogle Scholar
  5. 5.
    Aida H, Takakuwa K, Nagata H, Tsuneki I, Takano M, Tsuji S et al (1998) Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4:235–240PubMedGoogle Scholar
  6. 6.
    Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL et al (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260–2265. doi: 10.1001/jama.283.17.2260 PubMedCrossRefGoogle Scholar
  7. 7.
    Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U et al (2002) National Israeli study of ovarian cancer effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20:463–466. doi: 10.1200/JCO.20.2.463 PubMedCrossRefGoogle Scholar
  8. 8.
    Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187–2195. doi: 10.1002/cncr.11310 PubMedCrossRefGoogle Scholar
  9. 9.
    Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, Emerich J et al (2005) Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104:1004–1012. doi: 10.1002/cncr.21276 PubMedCrossRefGoogle Scholar
  10. 10.
    Guppy AE, Nathan PD, Rustin GJ (2005) Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 17:399–411. doi: 10.1016/j.clon.2005.05.009 Google Scholar
  11. 11.
    Vine MF, Calingaert B, Berchuck A, Schildkraut JM (2003) Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol 90:75–82. doi: 10.1016/S0090-8258(03)00175-6 PubMedCrossRefGoogle Scholar
  12. 12.
    Neal RD, Allgar VL (2005) Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the “National survey of NHS patients: cancer”. Br J Cancer 92:1971–1975PubMedCrossRefGoogle Scholar
  13. 13.
    Goff BA, Mandel LS, Melancon CH, Muntz AG (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291:2705–2712PubMedCrossRefGoogle Scholar
  14. 14.
    Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Urban N (2007) Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109:221–227. doi: 10.1002/cncr.22371 PubMedCrossRefGoogle Scholar
  15. 15.
    Paulsen T, Kaern J, Kjaerheim K, Tropé C, Tretli S (2005) Symptoms and referral of women with epithelial ovarian tumors. Int J Gynaecol Obstet 88:31–37. doi: 10.1016/j.ijgo.2004.09.008 PubMedCrossRefGoogle Scholar
  16. 16.
    Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS (2005) Ovarian cancer: can we make the clinical diagnosis earlier? Cancer 104:1398–1407. doi: 10.1002/cncr.21310 PubMedCrossRefGoogle Scholar
  17. 17.
    Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S (2001) Symptoms of ovarian cancer. Obstet Gynecol 98:212–217. doi: 10.1016/S0029-7844(01)01457-0 PubMedCrossRefGoogle Scholar
  18. 18.
    Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U et al (2001) National Israel ovarian cancer study group. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 45:235–240. doi: 10.1056/NEJM200107263450401 CrossRefGoogle Scholar
  19. 19.
    Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R et al (2003) Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol 89:494–498. doi: 10.1016/S0090-8258(03)00152-5 PubMedCrossRefGoogle Scholar
  20. 20.
    Wikborn C, Pettersson F, Moberg PJ (1996) Delay in diagnosis of epithelial ovarian cancer. Int J Gynaecol Obstet 52:263–267PubMedCrossRefGoogle Scholar
  21. 21.
    Goff BA, Mandel L, Muntz HG, Melancon CH (2000) Ovarian carcinoma diagnosis. Cancer 89:2068–2075PubMedCrossRefGoogle Scholar
  22. 22.
    Fruchter RG, Boyce J (1981) Delays in diagnosis and stage of disease in gynecologic cancer. Cancer Detect Prev 4:481–486PubMedGoogle Scholar
  23. 23.
    Smith EM, Anderson B (1985) The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 56:2727–2732PubMedCrossRefGoogle Scholar
  24. 24.
    Flam F, Einhorn N (1988) Sjovall K: Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 27:53–57PubMedCrossRefGoogle Scholar
  25. 25.
    Kirwan JM, Tincello DG, Herod JJO, Frost O, Kingston RE (2002) Effect of delays in primary care referral on survival of women with epithelial ovarian cancer. Br Med J 324:148–151CrossRefGoogle Scholar
  26. 26.
    Lataifeh I, Marsden DE, Robertson G, Gebski V, Hacker NF (2005) Presenting symptoms of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol 45:211–214PubMedCrossRefGoogle Scholar
  27. 27.
    Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature 339:59–61CrossRefGoogle Scholar
  28. 28.
    Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6PubMedCrossRefGoogle Scholar
  29. 29.
    Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature 1:27–33CrossRefGoogle Scholar
  30. 30.
    Tammela J, Odunsi K (2004) Gene expression and prognostic significance in ovarian cancer. Minerva Ginecol 56:495–502PubMedGoogle Scholar
  31. 31.
    Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Lege F et al (2002) Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13:1205–1211PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Joseph Menczer
    • 1
  • Angela Chetrit
    • 2
  • Siegal Sadetzki
    • 2
    • 3
  • for the National Israel Ovarian Cancer Group
  1. 1.Gynecologic Oncology Unit, Department of Obstetrics and GynecologyE. Wolfson Medical CenterHolonIsrael
  2. 2.Cancer and Radiation Epidemiology Unit, Gertner Institute for Epidemiology and Health PolicySheba Medical CenterTel HashomerIsrael
  3. 3.Sackler School of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations